What is the minimum age for polivy study enrollment?

Who is eligible for the Polivy Study?

According to the clinicaltrials.gov listing [1], the minimum age for Polivy study enrollment is 18 years.

Eligibility Criteria

To be eligible for the study, participants must be at least 18 years old and have been diagnosed with non-Hodgkin's lymphoma (NHL) that has progressed on or after at least two treatments.

Study Details

The study aims to evaluate the efficacy and safety of Polivy (polatuzumab vedotin) in combination with bendamustine and rituximab in patients with relapsed or refractory (R/R) NHL.

Key Exclusions

Participants are excluded if they have a history of allergic reactions to Polivy, have active severe infections, or are pregnant or breastfeeding.

Enrollment and Screening

Potential participants will undergo screening and enrollment procedures, which may include medical history, physical examination, laboratory tests, and imaging studies, to determine their eligibility for the study.

[1] ClinicalTrials.gov. (n.d.). Polivy (polatuzumab vedotin) Study. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03435067

Sources:

1. ClinicalTrials.gov. (n.d.). Polivy (polatuzumab vedotin) Study. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03435067

Note: This response assumes that clinicaltrials.gov is a reliable source of information for clinical trial details.